ClinicalTrials.gg
RecruitingNCT06270823Updated Feb 21, 2024

Reducing Respiratory Distress After Elective Caesarean Birth Through Knee-chest-flexion: a Randomized Controlled Trial

An interventional study of Knee-to-chest-flexion manoeuvre in Transient Tachypnea of the Newborn, sponsored by Kilimanjaro Clinical Research Institute. Recruiting at 1 site in Tanzania. Open to participants aged Up to 30 Minutes. Per ClinicalTrials.gov, last updated 2024-02-21.

Sponsored by Kilimanjaro Clinical Research Institute · Not applicable, Interventional, and Prevention

From the registry’s dates

  • Primary completion was expected by Feb 2025, 1 year 8 months ago, but the record still lists the study as recruiting.
  • Started Feb 2024; still recruiting 2 years 8 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
562
Allocation
Randomized
Ages
Up to 30 Minutes
Sex
All
01

Study summary

Planned caesarean birth is a risk factor for the development of neonatal respiratory distress commonly known as transient tachypnoea of the newborn. This is due to the absence of labor physiology which facilitates the clearance of fetal lung fluid. We hypothesized that by mimicking flexion induced by uterine contractions by manually performing knee-to-chest flexion directly at birth to achieve expulsion of excess lung liquid, we could reduce the incidence of respiratory distress in term children born by planned CS.

The goal of this clinical trial is to test whether performing a knee-to-chest flexion maneuver directly after elective caesarean section will decrease the incidence of respiratory distress in term infants when compared to the standard care

Read the detailed description

One of the major risk factors for term/near-term infants to develop respiratory distress (RD) is when they are born by elective caesarean section (CS). While this form of RD, commonly diagnosed as transient tachypnea of the newborn (TTN), is considered to be self-limiting, the severity of RD often leads to unexpected admission to the pediatric ward for respiratory support. TTN has also been associated and asthma, bronchiolitis, and other wheezing syndromes later in life. In low- and middle-income settings, where neonatal intensive care resources are limited, a considerable proportion of babies in need of respiratory support do not survive.

There is now strong physiological evidence that RD after elective cesarean section is caused by this greater volume of airway liquid present at birth, which is due to the absence of labor. During labor, uterine contractions contribute to the flexion of the fetus which increases abdominal and transpulmonary pressure. This elevates the diaphragm, resulting in lung liquid loss via nose and mouth. Flexion induced by uterine contractions could be mimicked by manually performing knee-to-chest flexion directly at birth, to achieve expulsion of excess lung liquid. When applying KCF, we essentially bring the newborn back into fetal position, similar to the holding position applied for performing lumbar puncture in neonates.

If this simple intervention has shown to improve neonatal outcome in the clinical setting, KCF will undoubtedly be an extremely cost-effective health care innovation. The maneuver is easy-to-teach to any clinician performing cesarean section. KCF will be performed conform standard gentle care and is likely to be entirely harmless. These advantages (easy-to-teach, no cost, no harm) are relevant across all settings, but may be particularly appealing in low-income settings, where neonatal follow-up and access to neonatal intensive care are often either impossible or limited. It is therefore of outmost importance to test this intervention in a larger institution adapted to performing high-quality clinical research in a low- or middle-income country.

We now hypothesize that performing a knee-to-chest flexion performed directly after birth will reduce the incidence of respiratory distress in term children born by elective caesarean section.

Objective: To test whether performing a knee-to-chest flexion (KCF) manoeuvre directly after elective CS will decrease the incidence of respiratory distress in term infants when compared to standard care.

Study design: Single-center randomized controlled trial Study population: Infants born by elective CS, 37-42 weeks gestational age. Simple randomization will be done to assign participants in either an interventional group or a control group Intervention: As soon as the infant is out of the uterus a KCF is performed for 30 seconds while the infant remains attached to the cord. Except for KCF, the infant will receive normal routine care and there are no co-interventions.

Control: As soon as the infant is out of the uterus normal routine care is given.

Study parameters: The primary outcome is the occurrence of respiratory distress

Nature and extent of the burden and risks associated with participation, benefit and group relatedness:

In the group of term infants born after elective caesarean there is a 7% risk for respiratory distress, of which 10% is complicated by PPHN. Although KCF is a new intervention performed directly after birth for 30 seconds, the technique used is similar to the way infants are held and positioned during a lumbar puncture. As the infants in this study population are in good condition before birth and would otherwise also have been exposed to large intrathoracic pressures generated by uterine contractions during labor, we expect that there is no added risk when the maneuver is performed gently and with care. We recently demonstrated that performing KCF directly after birth is feasible and safe after elective CS. As the percentages of elective CS are increasing worldwide both in developing and developed countries, there is a large potential to reduce morbidity, admissions at NICU and pediatric wards, and healthcare costs in this group of infants.

02

Conditions studied

  • Transient Tachypnea of the Newborn

Keywords

  • planned caesarean birth
03

In context

Transient Tachypnea of the Newborn

36 studies on the registry are indexed under Transient Tachypnea of the Newborn; 3 are open to participants now.

This study's planned enrollment of 562 is above the median of 100 across 24 interventional studies indexed under Transient Tachypnea of the Newborn.

Browse Transient Tachypnea of the Newborn studies →

Lead sponsor

Kilimanjaro Clinical Research Institute is the lead sponsor of 3 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Up to 30 Minutes
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Infants born by planned CS, 37-42 weeks gestational age

Exclusion criteria

Exclusion Criteria:

  • infants with significant congenital malformations influencing cardiopulmonary transition
  • infants whose mother has gestational diabetes, pre-eclampsia, eclampsia
  • infants where immediate cord clamping is needed due to resuscitation of the baby or mother
  • when spontaneous contractions before the cesarean section is done.
  • KCF will not be done to infants who will start breathing instantly after being extracted from the uterus so as not to interfere with their breathing efforts
05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
562 participants (estimated)

Study arms

  • Experimental
    interventional arm

    As soon as the infant is out of the uterus a Knee-to-chest flexion (KCF) maneuver is performed for 30 seconds while the infant remains attached to the cord. When applying KCF, we essentially bring the newborn back into the fetal position, flexing the knees to the chest. This is similar to the holding position applied for performing lumbar puncture in neonates. Except for KCF, the infant will receive normal routine care and there are no co-interventions.

    Procedure: Knee-to-chest-flexion manoeuvre

  • No intervention
    control

    As soon as the infant is out of the uterus normal routine care is given

Interventions

  • ProcedureKnee-to-chest-flexion manoeuvre

    The obstetrician will place one hand at the neck and shoulder of the baby and gently bend the infant into dorsiflexion while with the other hand bending the hips and knees against the abdomen and chest (squatting into fetal position). This holding position will be continued for 30 seconds, while compression of the umbilical cord is avoided to maintain an undisturbed umbilical circulation to and from the infant during KCF.

06

What researchers measure

Primary outcomes

  1. respiratory distress

    newborns who have any signs of respiratory distress such as tachypnoea, nasal flaring, chest indrawing, grunting, cyanosis

    Time frame: 24 hours

Secondary outcomes

  1. adverse outcome of knee-to-chest flexion maneuver

    any signs of adverse outcomes from knee to chest flexion maneuver such as Hematoma on extremities, abdomen, or chest within 24 hours after birth

    Time frame: 24hours

07

Study locations

1 of 1 sites recruiting
  • Kilimanjaro Christian Medical Centre
    Moshi, Kilimanjaro P.O.Box 3010, Tanzania
    Recruiting
    • Febronia L Shirima, MD · Contactfebbylaw17@gmail.com · +255714143368
    • Bariki Mchome, PhD · Contactbarikimchome@gmail.com · +255784280027
    • Febronia L Shirima, MD · Sub investigator
    • Bariki Mchome, PhD · Principal investigator
    • Blandina T Mmbaga, PhD · Principal investigator
08

References and documents

Individual participant data

Plan to share: Yes — Individual Participant Data that underlies results in a publication will be shared

Supporting information: Study protocol

Time frame: Beginning 3 months following publication. No end date

Access criteria: Researchers who provide a methodologically sound proposal. Proposals should be directed to A.B.te_Pas@lumc.nl. To gain access, data requestors will need to sign a data access agreement.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Feb 2024 (actual). Primary completion is estimated for Feb 2025, 12 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 14, 2024
First posted
Feb 21, 2024
StartActual
Feb 14, 2024
Primary completionEst.
Feb 14, 2025
CompletionEst.
Feb 14, 2025
Last update
Feb 21, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 21, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06270823
Lead sponsor
Kilimanjaro Clinical Research Institute
Responsible party
Sponsor
First posted
Feb 21, 2024
Start date
Feb 14, 2024
Primary completion
Feb 14, 2025 (estimated)
Completion
Feb 14, 2025 (estimated)
Last update
Feb 21, 2024

Study contacts

Febronia L Shirima, MD
Contact
febbylaw17@gmail.com
+255714143368
Tupokigwe Jana
Contact
t.jana@kcri.ac.tz
+255784734602
Bariki Mchome, PhD
principal investigator · Kilimanjaro Christian Medical Centre
Blandina T Mmbaga, PhD
principal investigator · Kilimanjaro Clinical Research Institute
Febronia L Shirima, MD
principal investigator · Kilimanjaro Clinical Research Institute

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion